Jes Lindholt’s Post

Chronic Venous Insufficiency Market Growth Anticipated by 2034 | Companies includes Verigraft, MediWound, TissueTech, Amniox Medical: Chronic Venous Insufficiency Market Several factors are expected to accelerate the growth of the Chronic Venous Insufficiency market during the forecast period (2023–2034). Increased awareness about available treatments, rising disease prevalence, and heightened disease awareness are key drivers. In the … Continue reading → #Business #Europe #HealthMedicine #PharmaceuticalsBiotech #US

Long-term use of finerenone is anticipated to increase the duration of event-free survival by as much as 3 years for individuals with heart failure and mildly reduced or preserved ejection fraction. Vaduganathan M, Claggett BL, Desai AS, et al. Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. Published online September 27, 2024. doi:10.1001/jamacardio.2024.3782

Article Title: Navigating the Triad: Large Pericardial Effusion, Pulmonary Embolism, and CMV Seropositivity in a Challenging Clinical Scenario- A Case Report   Journal of Case Reports and Medical History (JCRMH) Acquire Publications Authors: S Zahri Abstract This case study highlights the unusual coexistence of a large pericardial effusion, pulmonary embolism, and Cytomegalovirus (CMV) seropositivity in a 52-year-old active smoker. The complex interplay between cardiovascular and infectious etiologies in this triad poses diagnostic and therapeutic challenges. Through systematic analysis, this report aims to add valuable insights to the limited literature on this complex clinical scenario. For full Article visit https://lnkd.in/gpeKguYS

Editor's choice! 📖 Epirubicin for DEB-TACE: Prospective, single-arm, multicentre study on 108 patients with HCC that were treated with small size Edirubicin eluting beads in 199 procedures reveals satisfactory 12 month oncologic outcomes with no unanticipated adverse events. However, 30 serious adverse events occurred including five cases of hepatic abscess formation. https://lnkd.in/dg3HR-4e

Transforming the way we approach fatty liver disease isn't just about better diagnostics—it's about redefining patient care for a healthier tomorrow. 🌟 The shift from NAFLD to MAFLD in medical terminology not only marks a pivotal change in our understanding but also highlights the critical role of metabolic dysfunction in this condition, underlining the importance of personalized treatment strategies. At Arrow Dx, we're not just diagnosing fatty liver disease early; we're tailoring interventions to individual metabolic profiles, pioneering a future where care is as unique as each patient's DNA. 🧬💡 This terminology change from NAFLD to MAFLD is not just semantic; it signifies a deeper comprehension of the disease and a more focused approach to treatment. Dive deeper into how biotech innovations are paving the way for personalized medicine in our latest blog. Read now: https://lnkd.in/edAvAiqc #FattyLiverDisease #PersonalizedMedicine #ArrowDxInnovation

In the upcoming posters I’ll share the work we did in some of the papers and hope to share valuable Evidence-based lessons: Weekly Research paper Title: The Effect of Iron Replacement Therapy on HbA1c Levels in Diabetic and Nondiabetic Patients: A Systematic Review and Meta-Analysis The amazing team: Dr Amani M. AlQarni, Dr Amal A. Alghamdi, Dr Hussain Aljubran , Dr Abdullah H. Abuzaid and Dr Mohammed A. AlYahya Questions: 1- Iron deficiency anemia (IDA) elevates Hemoglobin A1c (HbA1c) in diabetic and non-diabetic patients? Yes 2-Is the severity of IDA (lower hemoglobin) correlated with a linear increase in HbA1c? Yes 3-If we had a diabetic or an non diabetic patient and we treated them with Iron replacement therapy (IRT), will the HbA1c decrease? Yes 4-What are the routes of IRT? And if we prolonge their administration will it further decrease HbA1c? Oral and Intravenous, as far as the data shows it decreases up to 1.2% Clinical pearl: Managing IDA with IRT in diabetic patients with elevated HbA1c can help in decreasing its level and control. For further information, please check: Poster: https://lnkd.in/deyvScFm Paper: https://lnkd.in/dpAhzDPN

Today at #EHA2024, clinical data from the Phase 1/2 EdiTHAL trial of reni-cel in patients with transfusion-dependent beta thalassemia will be presented in a poster presentation. Learn more: http://bit.ly/3WBoV0T #EHA2024 #geneediting #thalassemia

🧬 Discover at INASL 2024 from August 7-10 to explore our poster presentation titled "One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk population" using the OWLiver test. This innovative approach aims to improve the accuracy and ease of diagnosing these conditions, offering significant benefits for patient care and management. Our test demonstrates high sensitivity (86.1%) and positive predictive value (85.3%) for detecting MASH. The OWLiver Panel shows reliable accuracy in identifying MASH and significant fibrosis among high-risk individuals. This advancement in non-invasive diagnostics can revolutionize how we approach liver health and patient care.🔬 🗣️ Don't miss this opportunity to learn more about how our work can impact liver health and the future of medical diagnostics during the oral presentation of the poster on the Session - Special Interest Group (SIG) – MASLD the 9th August from 8:00 AM – 8.50 AM in Hall – 1. #INASL2024 #LiverHealth #Metabolomics #MedicalInnovation #Healthcare

🏅We would like to invite you to read this #editorschoice #review by Giosiana Bosco et al. Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice 🔗More info: https://brnw.ch/21wMLXK 📑This article belongs to the Special Issue Dyslipidemia and Cardiovascular Disease. For more papers from this Special Issue, please visit: https://brnw.ch/21wMLXJ #clinical #medicine #openaccess #statinintolerance #cardiovascularriskreduction

Delta4 is at the forefront of supporting the AustRian RESistanT NEPHROtic Syndrome Treatment Response RegIStry and Biobank. Nephrotic syndrome, a complex kidney condition, affects millions worldwide, leading to urinary protein loss, blood dysproteinemia, fluid retention, and impaired kidney function. 🩺 Join us in achieving these vital goals: 1️⃣ Gathering real-world data on practice patterns and outcomes. 2️⃣ Creating a supportive network for affected patients, families, and clinicians. 3️⃣ Building a patient base for enhanced recruitment in drug, medical device, and product studies. 4️⃣ Establishing a Biobank to enable research on potential biomarkers and therapy options. If you know someone affected by nephrotic syndrome, empower them to contribute to our life-changing registry. Reach out to the study contacts listed in the link. Together, we're innovating for better treatments. 🤝 Learn more ➡️ https://lnkd.in/dZe3-5Dq #Delta4 #NephroticSyndromeResearch #PatientSupport #HealthcareInnovation